Developing treatments for obsessive-compulsive disorder (OCD)
Sirgartan believes that mental illness should no longer be underestimated and stigmatized.
About Sirgartan
Sirgartan Therapeutics is an early-stage drug development company established in 2020 with the vision to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with OCD and other related neuropsychiatric disorders. The company’s mission is to identify and develop innovative single or combination treatments for OCD in conjunction with the world-leading neurological research resource provided by the University of Cambridge, UK..
Show MoreSirgartan Therapeutics is an early-stage drug development company established in 2020 with the vision to transform the treatment paradigm for OCD (obsessive compulsive disorder) and deliver life-changing medicines for patients with OCD and other related neuropsychiatric disorders. The company’s mission is to identify and develop innovative single or combination treatments for OCD in conjunction with the world-leading neurological research resource provided by the University of Cambridge, UK.
Sirgartan is also investigating other potential neurological disorder therapies in conjunction with the Cambridge Consulting Network (CCN). These will constitute the pipeline for further studies into mental illnesses, including eating disorders, body dysmorphia and a range of other less recognised, but highly debilitating conditions.
Investment obtained through initial seed-funding has enabled early- stage pre-clinical studies to be carried out by the University of Cambridge. These studies have shown very encouraging results, much to the satisfaction of Professor Trevor Robbins, Chief Scientific Advisor to Sirgartan. This has led to the recent submission of a patent application for the identified therapy and its method of action.
The organisation is now seeking further funding to enable progression into clinical studies in 2023. Please contact us at investors@sirgartan.com should you or your organisation have an interest in investing in this opportunity.
Why OCD?
Obsessive-Compulsive Disorder (OCD) is a common, chronic and long-lasting mental health condition in which a person experiences uncontrollable, intrusive and reoccurring thoughts (obsessions) and behaviours (compulsions) that (s)he feels the urge to repeat over and over, in the attempt to temporarily relieve the unpleasant feelings brought on by the obsessive thought.
OCD is the fourth most common mental disorder after depression, alcohol/substance misuse, and social phobia/anxiety.
According to the World Health Organisation, it is one of the 10 most disabling of all medical disorders.
It affects 2-3% of the population, women, men and children.
The condition typically starts during adolescence and early adulthood, although symptoms can develop at any age.
Once the condition has developed, it interferes significantly with the person’s life (or with the development of a child) and puts a great social and economic burden on the person and their environment.
OCD symptoms can range from mild to severe. Some people with OCD may spend a couple of hours a day engaged in obsessive-compulsive thinking and behaviour, for others the condition can completely take over their lives.
Existing treatments (medication and psychotherapeutic) are out-dated and usually only partially successful. Up to 30%–40% of patients do not respond to the available treatment options.
Sirgartan believes that mental illness should no longer be underestimated and stigmatized. Novel treatments and therapies are desperately needed, and resources invested into their development will be repaid by economic and social growth of a healthier society.
Glutamatergic drugs, such as the one targeted by Sirgartan, are also being studied as treatments for a number of psychiatric disorders and have important potential in the treatment of obsessive-compulsive disorder (OCD). This drug, if brought to market, could be life-changing for the millions of OCD patients showing resistance to available treatments.
The Team
Nick Sireau, PhD
(CEO and Co-founder)
Chair and Co-founder of Orchard, a non-profit focused on accelerating research into OCD and…
Vincenzo Garzya, MBA
(Co-founder and Advisor)
Head of Business Planning & Operations and Chief of Staff for Data Science and AI at…
Prof Trevor Robbins
(Chief Scientific Advisor)
Professor Robbins works in the areas of neuropsychopharmaco- logy and behavioural and…
David Cavalla, PhD
(Executive Chairman)
Serial Entrepreneur, Drug Development professional and expert on Drug Repurposing…
Dr Anthony Hall
(Chief Medical Officer)
Dr Anthony Hall is Chief Medical Officer at Sirgartan Therapeutics. He graduated from…
Christa van Kan
(Director of Clinical Operations)
Christa van Kan has more than 25 years of experience in managing clinical trials in a broad range of…
Prof Jon Grant
(OCD Expert and Clinical Advisor)
Jon E. Grant is a Professor of Psychiatry & Behavioral Neuroscience at the…
Lisa Stone
(Investor Relations Advisor)
Lisa Stone has a strong record as a financial and operational leader, with experiences spanning venture…
Julia Jones
(Chief Finance Advisor)
Founder and Managing Director at Archangel Accounting Ltd, Julia has over 20 years’ experience as…
Ekaterina Malievskaia
(Business Advisor)
Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg…
Our mission is improving treatment options for OCD
(obsessive-compulsive disorder)
a field which has historically been underfunded
and seen limited innovation.